Results of Infrapopliteal Endovascular Procedures Performed in Diabetic Patients with Critical Limb Ischemia and Tissue Loss from
the Perspective of an Angiosome-Oriented Revascularization Strategy
Table 8
TASC-II classification for the worst lesion treated and perioperative data according to the local perfusion of the ischemic ulcer.
Perioperative data
value
DR+ ()
IRμ “through collaterals” ()
IRμ “without collaterals” ()
DR+ versus IR “through collaterals”
DR+ versus IRµ “without collaterals”
IRμ “through collaterals versus IRμ “without collaterals”
TASC-B
3 (6.5%)
3 (13.6%)
0 (0%)
0.38
0.55
0.24
TASC-C
4 (8.7%)
3 (13.6%)
4 (23.5%)
0.67
0.19
0.67
TASC-D
39 (84.8%)
16 (72.7%)
13 (76.5%)
0.23
0.46
0.79
Combined treatment*
20 (43.5%)
7 (31.8%)
3 (17.6%)
0.06
0.009
0.46
Debridement
4 (8.7%)
2 (9.1%)
2 (11.8%)
0.95
0.65
0.78
Minor amputation
12 (26.1%)
7 (31.8%)
3 (17.6%)
0.62
0.74
0.46
Multiple revascularization
31 (67.4%)
8 (36.4%)
7 (41.2%)
0.01
0.06
0.75
Runoff 1
28 (60.9%)
20 (90.9%)
16 (94.1%)
0.01
0.01
0.70
Runoff > 1
18 (39.1%)
2 (9.1%)
1 (5.9%)
0.01
0.01
0.70
Postoperative ABI#
0.85 (0.70–0.95)
0.91 (0.82–0.95)
0.80 (0.65–0.91)
0.30
0.79
0.48
MACE† at 30 days
1 (2.2%)
2 (9.1%)
0 (0%)
0.24
0.54
0.49
MALE& at 30 days
1 (2.2%)
1 (4.5%)
1 (5.9%)
0.54
0.47
0.85
Major amputation at 30 days
1 (2.2%)
1 (4.5%)
0 (0%)
0.54
0.73
0.37
*Combined treatment: combined treatment of the femoropopliteal and the infrapopliteal sector; #ABI: ankle-brachial index; †MACE: major adverse cardiovascular event; &MALE: major adverse limb event; +DR: direct revascularization; μIR: indirect revascularization.
